Andrew Cheng
Vorstandsvorsitzender bei AKERO THERAPEUTICS, INC.
Vermögen: 12 Mio $ am 30.04.2024
Aktive Positionen von Andrew Cheng
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
AKERO THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.09.2018 | - |
Vorstandsvorsitzender | 01.09.2018 | - | |
Präsident | 01.09.2018 | - | |
VERA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.05.2017 | - |
Independent Dir/Board Member | 01.05.2017 | - | |
MORPHOSYS AG | Direktor/Vorstandsmitglied | 18.05.2022 | - |
Boys & Girls Clubs of Metro Los Angeles
Boys & Girls Clubs of Metro Los Angeles Miscellaneous Commercial ServicesCommercial Services Boys & Girls Clubs of Metro Los Angeles is a non-profit organization that was founded in December 2015 to provide a sustainable solution to the opportunity crises facing vulnerable children in the neediest neighborhoods of Los Angeles. Boys & Girls Clubs of Metro Los Angeles is based in Los Angeles, CA, and has subsidiaries in the United States. The organization operates four clubs in Bell Gardens, Challengers, Downs, and Willowbrook, and offers nationally recognized, research-based programs and activities in three core areas: academic success, good character and citizenship, and healthy lifestyles. The organization empowers youth to explore a future with endless possibilities by offering creative programming, such as new approaches to science, technology, engineering, and math (STEM) created in collaboration with community partners. The non-profit company was founded in 2015, and the CEO is Patrick Mahoney. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Andrew Cheng
Ehemalige bekannte Positionen von Andrew Cheng
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ARBUTUS BIOPHARMA CORPORATION | Direktor/Vorstandsmitglied | 20.08.2019 | 25.05.2022 |
Independent Dir/Board Member | 20.08.2019 | 25.05.2022 | |
GILEAD SCIENCES, INC. | Technik-/Wissenschafts-/F&E-Leiter | - | 07.09.2018 |
Corporate Officer/Principal | 01.01.1999 | - | |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Direktor/Vorstandsmitglied | 25.04.2018 | - |
Global Virus Network
Global Virus Network Miscellaneous Commercial ServicesCommercial Services Global Virus Network conducts research on essential and critical defense against viral diseases. The non-profit company is based in Baltimore, MD. The company was founded by William Walmsley Hall and Robert C. Gallo. | Direktor/Vorstandsmitglied | - | - |
Ausbildung von Andrew Cheng
The Johns Hopkins University | Undergraduate Degree |
Columbia University College of Physicians & Surgeons | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 10 |
Deutschland | 2 |
Operativ
Director/Board Member | 7 |
Independent Dir/Board Member | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Sektoral
Health Technology | 7 |
Consumer Services | 3 |
Commercial Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 5 |
---|---|
GILEAD SCIENCES, INC. | Health Technology |
AKERO THERAPEUTICS, INC. | Health Technology |
ARBUTUS BIOPHARMA CORPORATION | Health Technology |
VERA THERAPEUTICS, INC. | Health Technology |
MORPHOSYS AG | Health Technology |
Private Unternehmen | 3 |
---|---|
Global Virus Network
Global Virus Network Miscellaneous Commercial ServicesCommercial Services Global Virus Network conducts research on essential and critical defense against viral diseases. The non-profit company is based in Baltimore, MD. The company was founded by William Walmsley Hall and Robert C. Gallo. | Commercial Services |
Syntimmune, Inc.
Syntimmune, Inc. BiotechnologyHealth Technology Syntimmune, Inc. engages in the research and development of therapeutics for autoimmune diseases based on neonatal Fc receptor biology. Its pipeline include SYNT001 which has target indication for dermatology, hematology, and neurology. It also focuses on pre-clinical investigation of SYTN002 and related compounds such as peptide mimetics. The company was founded by Laurence J. Blumberg and Richard S. Blumberg in 2013 and is headquartered in Boston, MA. | Health Technology |
Boys & Girls Clubs of Metro Los Angeles
Boys & Girls Clubs of Metro Los Angeles Miscellaneous Commercial ServicesCommercial Services Boys & Girls Clubs of Metro Los Angeles is a non-profit organization that was founded in December 2015 to provide a sustainable solution to the opportunity crises facing vulnerable children in the neediest neighborhoods of Los Angeles. Boys & Girls Clubs of Metro Los Angeles is based in Los Angeles, CA, and has subsidiaries in the United States. The organization operates four clubs in Bell Gardens, Challengers, Downs, and Willowbrook, and offers nationally recognized, research-based programs and activities in three core areas: academic success, good character and citizenship, and healthy lifestyles. The organization empowers youth to explore a future with endless possibilities by offering creative programming, such as new approaches to science, technology, engineering, and math (STEM) created in collaboration with community partners. The non-profit company was founded in 2015, and the CEO is Patrick Mahoney. | Commercial Services |
- Börse
- Insiders
- Andrew Cheng
- Erfahrung